PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $212,000 | -9.0% | 10,867 | -17.6% | 0.02% | -8.0% |
| Q2 2020 | $233,000 | +65.2% | 13,189 | -23.0% | 0.02% | +108.3% |
| Q1 2020 | $141,000 | +18.5% | 17,122 | +1.0% | 0.01% | +20.0% |
| Q4 2019 | $119,000 | -46.4% | 16,947 | -8.4% | 0.01% | -47.4% |
| Q3 2019 | $222,000 | -9.4% | 18,511 | -8.6% | 0.02% | -9.5% |
| Q2 2019 | $245,000 | -5.4% | 20,244 | -1.7% | 0.02% | 0.0% |
| Q1 2019 | $259,000 | +46.3% | 20,599 | -21.8% | 0.02% | +50.0% |
| Q4 2018 | $177,000 | -50.1% | 26,335 | -29.4% | 0.01% | -36.4% |
| Q3 2018 | $355,000 | +50.4% | 37,299 | +6.2% | 0.02% | +57.1% |
| Q2 2018 | $236,000 | – | 35,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |